Understand what your general health testing results really mean
See your biomarkers in context with a comprehensive panel.
- CLIA-certified labs
- HIPAA compliant
- Personalized health protocol
A negative ANA makes autoimmune disease unlikely. About 13-14% of healthy U.S. adults test positive at 1:80. A titer of 1:160 or higher with symptoms warrants follow-up.
How titer and staining pattern work
Your ANA test measures two critical components: titer levels and staining patterns. Think of titer as the dilution strength where your antibodies still show up. A 1:80 titer means your blood was diluted 80 times and still tested positive. A 1:160 titer required 160-fold dilution to detect antibodies.
| Titer | What it means |
|---|---|
| 1:40 | Below most labs' positive cutoff; common in healthy adults and usually background noise |
| 1:80 | Positive at most labs, though the cutoff varies; found in about 13-14% of healthy U.S. adults with no autoimmune disease |
| 1:160 | Yes, positive, and worth closer attention; may reflect autoimmune activity, especially with symptoms, but does not confirm active disease |
| 1:320 or higher | Same follow-up as 1:160, weighed with symptoms and pattern; most people with lupus test at 1:160 or higher |
The staining pattern reveals which part of the cell nucleus your antibodies target.
| Pattern | What it looks like | Associated conditions |
|---|---|---|
| Homogeneous | Smooth, even staining | Lupus or drug-induced autoimmunity; with joint pain and fatigue, may prompt lupus evaluation |
| Coarse speckled | Larger, chunky dots | Sjögren's syndrome, mixed connective tissue disease, or scleroderma; with dry eyes and mouth, could indicate Sjögren's syndrome |
| Dense fine speckled (DFS70) | Smaller, finer dots | Often seen in healthy people; generally not tied to autoimmune disease |
| Nucleolar | Concentrated dots | Scleroderma; with skin tightening, warrants scleroderma assessment |
| Centromere | Distinct paired dots | Limited cutaneous systemic sclerosis |
The combination of titer strength and specific pattern provides much more information than either measurement alone.
What a positive ANA HEp-2 result means
A positive ANA HEp-2 result means antinuclear antibodies were detected by indirect immunofluorescence (IFA) on HEp-2 cells, the widely used ANA screening method. A positive result does not confirm disease on its own. Your titer, staining pattern, and symptoms decide what it means.
Your healthcare provider will also factor in your age, sex, and family history. Women develop positive ANA results more frequently than men. Having relatives with autoimmune conditions increases your likelihood of developing them too.
Remember that positive ANA results can appear months or years before symptoms develop. This makes regular monitoring valuable, even when you feel perfectly healthy. All ANA results should be interpreted by healthcare professionals who can consider your complete clinical picture.
What can influence ANA test results
Several factors can create false positives or affect result interpretation. Age significantly impacts ANA prevalence. ANA prevalence rises meaningfully with age, from lower rates in young adults to roughly 15-25% in adults over 50-65, depending on titer cutoff and population studied. This age-related increase often reflects accumulated immune system changes rather than disease.
Medications can trigger positive results. Hydralazine, procainamide, and some anti-seizure drugs commonly are associated with drug-induced lupus with positive ANA. Birth control pills, antibiotics, and heart medications occasionally elevate ANA levels too.
Infections temporarily boost autoantibody production. Viral infections like Epstein-Barr virus, cytomegalovirus, or COVID-19 can create transient positive results. Bacterial infections and parasitic diseases sometimes trigger ANA production as well.
Laboratory variations affect results consistency. Different labs use different cell types, dilution protocols, and interpretation criteria. Always retest concerning results at the same laboratory when possible. Stress, pregnancy, and recent vaccinations can also influence antibody levels.
Test 100+ biomarkers
One blood draw. A full picture of your health, explained in plain language.
Test 100+ biomarkers
One blood draw. A full picture of your health, explained in plain language.
Follow-up antibody tests after a positive ANA
ANA results gain meaning when viewed alongside specific autoantibody tests. Anti-dsDNA antibodies with positive ANA may suggest lupus, especially with kidney involvement. Anti-SSA/SSB antibodies may indicate Sjögren's syndrome risk. Anti-Scl-70 antibodies may point toward diffuse scleroderma. Anti-centromere antibodies are associated with limited scleroderma.
Complement levels (C3 and C4) provide additional context. Low complement with positive ANA often indicates active autoimmune inflammation. Normal complement levels suggest less active disease, even with positive antibodies.
Inflammatory markers like ESR (erythrocyte sedimentation rate) and CRP (C-reactive protein) help distinguish between active autoimmune disease and benign positive results. Elevated inflammatory markers with positive ANA warrant more aggressive evaluation. CRP is often normal in uncomplicated lupus flares, so a markedly elevated CRP in someone with known SLE may point to infection or serositis rather than a classic lupus flare.
Your complete blood count can reveal autoimmune complications. Low white blood cell counts, anemia, or reduced platelets combined with positive ANA might indicate systemic lupus erythematosus. These patterns help your healthcare provider prioritize follow-up testing and monitoring strategies.
Take control of your autoimmune health
Tracking ANA over time, alongside immune and inflammatory markers, shows whether your results are stable or changing. Superpower's biomarker testing includes immune system markers, inflammatory indicators, and complement levels that add context to ANA results. Review them with your healthcare provider.
Frequently Asked Questions
References
- Damoiseaux J, Andrade LEC, Carballo OG, Conrad K, Francescantonio PLC, Fritzler MJ, Garcia de la Torre I, Herold M, Klotz W, Cruvinel WM, Mimori T, von Muhlen C, Satoh M, Chan EK (2019). Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective. *Annals of the rheumatic diseases*, *78*(7), 879-889. https://doi.org/10.1136/annrheumdis-2018-214436
- Mariz HA, Sato EI, Barbosa SH, Rodrigues SH, Dellavance A, Andrade LE (2011). Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases. *Arthritis and rheumatism*, *63*(1), 191-200. https://doi.org/10.1002/art.30084
- van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, Naden RP, Medsger TA, Carreira PE, Riemekasten G, Clements PJ, Denton CP, Distler O, Allanore Y, Furst DE, Gabrielli A, Mayes MD, van Laar JM, ... Pope JE (2013). 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. *Annals of the rheumatic diseases*, *72*(11), 1747-55. https://doi.org/10.1136/annrheumdis-2013-204424
- Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, ... Johnson SR (2019). 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. *Arthritis & rheumatology (Hoboken, N.J.)*, *71*(9), 1400-1412. https://doi.org/10.1002/art.40930
- Satoh M, Chan EK, Ho LA, Rose KM, Parks CG, Cohn RD, Jusko TA, Walker NJ, Germolec DR, Whitt IZ, Crockett PW, Pauley BA, Chan JY, Ross SJ, Birnbaum LS, Zeldin DC, Miller FW (2012). Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. *Arthritis and rheumatism*, *64*(7), 2319-27. https://doi.org/10.1002/art.34380
- Selmi C, Ceribelli A, Generali E, Scirè CA, Alborghetti F, Colloredo G, Porrati L, Achenza MI, De Santis M, Cavaciocchi F, Massarotti M, Isailovic N, Paleari V, Invernizzi P, Matthias T, Zucchi A, Meroni PL (2016). Serum antinuclear and extractable nuclear antigen antibody prevalence and associated morbidity and mortality in the general population over 15 years. *Autoimmunity reviews*, *15*(2), 162-6. https://doi.org/10.1016/j.autrev.2015.10.007
- Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, Rasmussen A, Scofield H, Vitali C, Bowman SJ, Mariette X, International Sjögren's Syndrome Criteria Working Group (2017). 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts. *Arthritis & rheumatology (Hoboken, N.J.)*, *69*(1), 35-45. https://doi.org/10.1002/art.39859
- Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, Harley JB (2003). Development of autoantibodies before the clinical onset of systemic lupus erythematosus. *The New England journal of medicine*, *349*(16), 1526-33. https://doi.org/10.1056/NEJMoa021933
- Vaglio A, Grayson PC, Fenaroli P, Gianfreda D, Boccaletti V, Ghiggeri GM, Moroni G (2018). Drug-induced lupus: Traditional and new concepts. *Autoimmunity reviews*, *17*(9), 912-918. https://doi.org/10.1016/j.autrev.2018.03.016
- Ding BN, Wu YL, Zhang YY, Li YG (2024). Association between Epstein-Barr virus infection and serum positivity rate of anti-nuclear antibodies in Chongqing, China: A cross-sectional observational study. *Medicine*, *103*(32), e39233. https://doi.org/10.1097/MD.0000000000039233
- Hromić-Jahjefendić A, Lundstrom K, Adilović M, Aljabali AAA, Tambuwala MM, Serrano-Aroca, Á., Uversky VN (2024). Autoimmune response after SARS-CoV-2 infection and SARS-CoV-2 vaccines. *Autoimmunity reviews*, *23*(3), 103508. https://doi.org/10.1016/j.autrev.2023.103508


















